メラノーマ（悪性黒色腫）治療薬の世界市場レポート 2024年

メラノーマ治療薬の市場規模は近年急速に拡大しています。2023年の82億7,000万米ドルから2024年には92億7,000万米ドルへと、CAGR12.1％で拡大します。このような成長は、臨床研究の進歩、罹患率の上昇、治療状況の変化、診断技術の向上、規制状況の改善によるものです。

メラノーマ治療薬市場規模は、今後数年で急成長が見込まれます。2028年には139億8,000万米ドルに成長し、CAGRは10.8％となります。予測期間中に予想される成長の背景には、免疫療法の進歩、進行中のバイオマーカー調査、世界人口の高齢化、新興国市場の拡大、共同研究イニシアティブなどがあります。本予測期間における注目すべき動向としては、補助療法の革新、チェックポイント阻害剤の利用拡大、患者層別化戦略、実臨床エビデンスの統合、臨床試験における世界の共同研究などが挙げられます。

男性のメラノーマ罹患率の増加が予想されることから、今後数年間、メラノーマ治療薬市場の成長が見込まれます。メラノーマは、色素を調節する細胞（メラノサイト）から発生する皮膚がんの一種であり、メラノーマ用に特別に設計された薬剤を使用して治療され、体内でのメラノーマ細胞の増殖と拡散を標的にして抑制することを目的としています。メラノーマの罹患率の増加は、メラノーマ治療薬の需要を高めると予想されます。2023年、米国がん協会（American Cancer Society, Inc.）は、米国における男性の新規症例の増加を報告し、2022年の57,180人から2023年には58,120人に増加しました。その結果、男性のメラノーマ症例の急増がメラノーマ治療薬市場の成長を促進する主要因となっています。

高齢化人口の増加は、今後のメラノーマ治療薬市場の成長を促進します。高齢化動向とは、社会における高齢者の割合の増加を特徴とする人口動態の変化を指します。メラノーマ治療薬は、高齢者の皮膚がんに対する懸念に対処し、治療成績を向上させる上で重要な役割を果たしています。2022年10月の時点で、世界保健機関は2030年までに世界の6人に1人が60歳以上になると予測しています。この間、60歳以上の人口は2020年の10億人から14億人に増加すると予想されています。さらに、世界の60歳以上の人口は倍増し、2050年には21億人に達すると予想されています。したがって、高齢化人口の拡大はメラノーマ治療薬市場の重要な促進要因です。

2023年のメラノーマ治療薬市場で最大の地域は北米でした。メラノーマ治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のメラノーマ治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 化学療法
• 免疫療法
• 標的療法
• 世界のメラノーマ治療薬市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 表在性メラノーマ
• レンチゴマリグナ
• 末端黒子型メラノーマ
• 結節性メラノーマ
• 世界のメラノーマ治療薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 腫瘍外来診療所
• その他の用途

第7章 地域および国の分析

• 世界のメラノーマ治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のメラノーマ治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• メラノーマ治療薬市場の競合情勢
• メラノーマ治療薬市場の企業プロファイル
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche A
  • GlaxoSmithKline plc
  • Janssen Biotech Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Melanoma Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on melanoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for melanoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The melanoma drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Therapy: Chemotherapy; Immunotherapy; Targeted Therapy
• 2) By Disease Type: Superficial Spreading Melanoma; Lentigo Maligna; Acral Lentiginous Melanoma; Nodular Melanoma
• 3) By Application: Hospitals; Outpatient Oncologist Clinics; Other Applications
• Companies Mentioned: Amgen Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche A; GlaxoSmithKline plc; Janssen Biotech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

A melanoma drug is a medication used for the treatment of skin cancer that originates in the cells responsible for producing melanin, the pigment determining skin, hair, and eye color. These drugs are employed to address melanoma by targeting and inhibiting the growth and dissemination of melanoma cells within the body.

The primary therapeutic approaches for melanoma drugs include chemotherapy, immunotherapy, and targeted therapy. Chemotherapy is a medical intervention utilizing drugs to either destroy or impede the growth of cancer cells. It stands as a key treatment option for cancer and is typically combined with other modalities such as surgery and radiation therapy. Melanoma drugs find application in treating various melanoma types, including superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma, and nodular melanoma, in settings such as hospitals, outpatient oncologist clinics, and others.

The melanoma drugs market research report is one of a series of new reports from The Business Research Company that provides melanoma drugs market statistics, including melanoma drugs industry global market size, regional shares, competitors with a melanoma drugs market share, detailed melanoma drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the melanoma drugs industry. This melanoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma drugs market size has grown rapidly in recent years. It will grow from $8.27 billion in 2023 to $9.27 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth observed in the historical period can be credited to advances in clinical research, heightened incidence rates, shifts in the treatment landscape, enhanced diagnostic techniques, and regulatory approvals.

The melanoma drugs market size is expected to see rapid growth in the next few years. It will grow to $13.98 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, ongoing biomarker research, the aging global population, the expansion of markets in emerging economies, and collaborative research initiatives. Notable trends in this forecast period include innovations in adjuvant therapies, increased utilization of checkpoint inhibitors, strategies for patient stratification, integration of real-world evidence, and global collaborations in clinical trials.

The anticipated increase in melanoma incidence among males is set to drive the growth of the melanoma drug market in the coming years. Melanoma, a form of skin cancer originating in pigment-regulating cells (melanocytes), is treated using medications specifically designed for melanoma, aiming to target and inhibit the growth and spread of melanoma cells within the body. The rising incidence of melanoma is expected to elevate the demand for melanoma drugs. In 2023, the American Cancer Society, Inc. reported a rise in new cases among male individuals in the United States, increasing from 57,180 in 2022 to 58,120 in 2023. Consequently, the surge in melanoma cases among males is a key driver propelling the growth of the melanoma drug market.

The increasing aging population is poised to propel the growth of the melanoma drug market in the future. An aging population trend refers to a demographic shift characterized by a growing proportion of elderly individuals within a society. Melanoma drugs play a crucial role in addressing skin cancer concerns and improving treatment outcomes in the elderly. As of October 2022, the World Health Organization projected that by 2030, 1 in 6 individuals globally would be 60 years old or older. During this period, the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Additionally, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Hence, the expanding aging population is a significant driver of the melanoma drug market.

Product innovation stands out as a notable trend gaining momentum in the melanoma drugs market. Major companies within the market are concentrating their efforts on developing innovative solutions to solidify their market position. For example, in March 2022, the U.S. Food and Drug Administration (FDA) approved Opdualag, a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab, developed by Bristol-Myers Squibb Company. This approval is for the treatment of melanoma in both adult and pediatric patients. Opdualag combines the antibodies relatlimab and nivolumab at a fixed dose, offering a breakthrough approach. Adult and adolescent patients aged 12 and older, weighing at least 40 kg, are recommended to receive 480 mg of nivolumab and 160 mg of relatlimab intravenously every four weeks until disease progression or unacceptable toxicity occurs.

Major companies in the melanoma drug market are prioritizing the development of breakthrough therapies, such as T cell receptor (TCR) therapeutics, to treat uveal melanoma and gain a competitive advantage. TCR therapeutics involve using engineered T cell receptors to redirect the immune system to recognize and target specific antigens, particularly in the context of cancer. For instance, in January 2022, Immunocore, a UK-based biotechnology company, received FDA approval for KIMMTRAK, the first FDA-approved therapy for unresectable or metastatic uveal melanoma. This TCR therapeutic demonstrated significant overall survival benefits in clinical trials, with a median OS of nearly 22 months. The approval marks several milestones, including being the first TCR therapeutic to receive FDA approval and the first bispecific T cell engager approved for the treatment of solid tumors.

In May 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, completed the acquisition of Checkmate Pharmaceuticals Inc. for $250 million. This strategic move aims to expand Regeneron Pharmaceuticals Inc.'s pipeline portfolio of immuno-oncology drugs and provide a new modality to treat challenging cancers. Checkmate Pharmaceuticals, Inc., a US-based biopharmaceutical company, specializes in mutant metastatic melanoma.

Major companies operating in the melanoma drugs market report are Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche A, GlaxoSmithKline plc, Janssen Biotech Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Genentech Inc., Merck & Co. Inc., Bayer AG, Bausch Health Companies Inc., Cipla Limited, Vical Incorporated, Aduro Biotech Inc., OSE Immunotherapeutics, Daiichi Sankyo Company Limited, Gilead Sciences, Seagen Inc., Incyte Corporation, Kyowa Kirin Co. Ltd., Almirall S.A., MacroGenics Inc., Prometheus Biosciences Inc., Fortress Biotech Inc., OncoSec Medical Incorporated, Regeneron Pharmaceuticals Inc., Iovance Biotherapeutics

North America was the largest region in the melanoma drugs market in 2023. The regions covered in the melanoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the melanoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The melanoma drug market consists of sales of pembrolizumab, nivolumab, vemurafenib, avelumab, and dabrafenib with trametinib drugs used for the treatment of melanoma. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Melanoma Drugs Market Characteristics

3. Melanoma Drugs Market Trends And Strategies

4. Melanoma Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Melanoma Drugs Market Size and Growth

• 5.1. Global Melanoma Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Melanoma Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Melanoma Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Melanoma Drugs Market Segmentation

• 6.1. Global Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• 6.2. Global Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Superficial Spreading Melanoma
• Lentigo Maligna
• Acral Lentiginous Melanoma
• Nodular Melanoma
• 6.3. Global Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Outpatient Oncologist Clinics
• Other Applications

7. Melanoma Drugs Market Regional And Country Analysis

• 7.1. Global Melanoma Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Melanoma Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Melanoma Drugs Market

• 8.1. Asia-Pacific Melanoma Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Melanoma Drugs Market

• 9.1. China Melanoma Drugs Market Overview
• 9.2. China Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Melanoma Drugs Market

• 10.1. India Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Melanoma Drugs Market

• 11.1. Japan Melanoma Drugs Market Overview
• 11.2. Japan Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Melanoma Drugs Market

• 12.1. Australia Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Melanoma Drugs Market

• 13.1. Indonesia Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Melanoma Drugs Market

• 14.1. South Korea Melanoma Drugs Market Overview
• 14.2. South Korea Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Melanoma Drugs Market

• 15.1. Western Europe Melanoma Drugs Market Overview
• 15.2. Western Europe Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Melanoma Drugs Market

• 16.1. UK Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Melanoma Drugs Market

• 17.1. Germany Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Melanoma Drugs Market

• 18.1. France Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Melanoma Drugs Market

• 19.1. Italy Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Melanoma Drugs Market

• 20.1. Spain Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Melanoma Drugs Market

• 21.1. Eastern Europe Melanoma Drugs Market Overview
• 21.2. Eastern Europe Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Melanoma Drugs Market

• 22.1. Russia Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Melanoma Drugs Market

• 23.1. North America Melanoma Drugs Market Overview
• 23.2. North America Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Melanoma Drugs Market

• 24.1. USA Melanoma Drugs Market Overview
• 24.2. USA Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Melanoma Drugs Market

• 25.1. Canada Melanoma Drugs Market Overview
• 25.2. Canada Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Melanoma Drugs Market

• 26.1. South America Melanoma Drugs Market Overview
• 26.2. South America Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Melanoma Drugs Market

• 27.1. Brazil Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Melanoma Drugs Market

• 28.1. Middle East Melanoma Drugs Market Overview
• 28.2. Middle East Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Melanoma Drugs Market

• 29.1. Africa Melanoma Drugs Market Overview
• 29.2. Africa Melanoma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Melanoma Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Melanoma Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Melanoma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Melanoma Drugs Market Competitive Landscape
• 30.2. Melanoma Drugs Market Company Profiles
  • 30.2.1. Amgen Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bristol-Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche A
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GlaxoSmithKline plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Janssen Biotech Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Melanoma Drugs Market Competitive Benchmarking

32. Global Melanoma Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Melanoma Drugs Market

34. Melanoma Drugs Market Future Outlook and Potential Analysis

• 34.1 Melanoma Drugs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Melanoma Drugs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Melanoma Drugs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer